Pharmaceutical giant Eli Lilly and Company has announced its agreement to acquire Engage Biologics, a California-based biotechnology firm, for a…
Read More
Takeda Ordered to Pay $885 Million in Landmark "Pay-for-Delay" Drug Case, Faces Potential $2.5 Billion Liability
In a groundbreaking verdict that could reshape pharmaceutical antitrust litigation, a U.S. jury has found Japanese pharmaceutical giant Takeda liable…
Read More
China Ascends to Global Clinical Trial Leadership as Immunology and Metabolic Diseases Emerge as Key Growth Areas
As the global pharmaceutical industry navigates the dynamic landscape of clinical research, China has firmly established its dominance in trial…
Read More
Global Healthcare Giants Unite: GHO Capital and CBC Group Forge Largest Dedicated Investment Manager with $21 Billion AUM
Two prominent forces in specialized healthcare investment, Global Healthcare Opportunities (GHO) and CBC Group, have announced a groundbreaking merger to…
Read More
QIAGEN Digital Insights Partners with NVIDIA to Revolutionize AI-Driven Drug Discovery
The integration of NVIDIA’s accelerated computing and BioNeMo platform with QIAGEN Digital Insights’ bioinformatics capabilities is poised to usher in…
Read More
The Evolving Landscape of Ovarian Cancer Research: Navigating Complexity and Embracing Global Strategies
The field of ovarian cancer research is undergoing a profound transformation, driven by significant advancements in personalized medicine and innovative…
Read More
Regeneron Pharmaceuticals and Parabilis Medicines Forge Landmark $2.32 Billion Collaboration to Pioneer a New Era of Intracellular Therapies
Regeneron Pharmaceuticals has announced a monumental research collaboration with Parabilis Medicines, a deal valued at an impressive $2.32 billion. This…
Read More
UK Secures Favipiravir Supply from Japan to Bolster Hantavirus Preparedness
The United Kingdom has received a crucial supply of the antiviral medication favipiravir from the Japanese government, a strategic move…
Read More
VERTANICAL’s Investigational Non-Opioid Chronic Low Back Pain Treatment VER-01 Receives FDA Breakthrough Therapy Designation
VERTANICAL has announced a significant milestone in its development of VER-01, an investigational non-opioid therapeutic candidate for chronic low back…
Read More
Japan Approves Jascayd (nerandomilast) for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
Boehringer Ingelheim has achieved a significant milestone in the treatment of interstitial lung diseases with the approval of Jascayd (nerandomilast)…
Read More
